Targeted Therapeutics in Melanoma:
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment...
Gespeichert in:
Format: | Elektronisch E-Book |
---|---|
Sprache: | English |
Veröffentlicht: |
Totowa, NJ
Humana Press
2012
|
Ausgabe: | 1st ed. 2012 |
Schriftenreihe: | Current Clinical Oncology
|
Schlagworte: | |
Online-Zugang: | UBR01 Volltext |
Zusammenfassung: | Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers |
Beschreibung: | Molecular targets and subtypes in melanoma -- Melanoma genomics -- Predictive biomarkers as a guide to future therapy selection in melanoma -- KIT as a therapeutic target for melanoma -- Targeted inhibition of B-Raf -- The notch and B-catenin pathways -- STAT3 and Src signaling in melanoma -- Targeting the mTOR, PI3K and AKT pathways in melanoma -- Targeting apoptotic pathways in melanoma -- Anti-angiogenesis therapy in melanoma -- Melanoma antigens recognized by T lymphocytes -- Melanoma vaccines -- Adoptive cell therapy for the treatment of metastatic melanoma -- Anti-CTLA-4 monolonal antibodies -- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co-stimulatory agents -- Novel cytokines for immunotherapy of melanoma -- Modulating the tumor microenvironment |
Beschreibung: | 1 Online-Ressource (XIV, 378 Seiten) Illustrationen |
ISBN: | 9781617794070 |
DOI: | 10.1007/978-1-61779-407-0 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV047645727 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 211216s2012 |||| o||u| ||||||eng d | ||
020 | |a 9781617794070 |9 978-1-61779-407-0 | ||
024 | 7 | |a 10.1007/978-1-61779-407-0 |2 doi | |
035 | |a (ZDB-2-SME)978-1-61779-407-0 | ||
035 | |a (OCoLC)1289776456 | ||
035 | |a (DE-599)BVBBV047645727 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-355 | ||
082 | 0 | |a 616.994 | |
245 | 1 | 0 | |a Targeted Therapeutics in Melanoma |c edited by Thomas F. Gajewski, F. Stephen Hodi |
250 | |a 1st ed. 2012 | ||
264 | 1 | |a Totowa, NJ |b Humana Press |c 2012 | |
300 | |a 1 Online-Ressource (XIV, 378 Seiten) |b Illustrationen | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
490 | 0 | |a Current Clinical Oncology | |
500 | |a Molecular targets and subtypes in melanoma -- Melanoma genomics -- Predictive biomarkers as a guide to future therapy selection in melanoma -- KIT as a therapeutic target for melanoma -- Targeted inhibition of B-Raf -- The notch and B-catenin pathways -- STAT3 and Src signaling in melanoma -- Targeting the mTOR, PI3K and AKT pathways in melanoma -- Targeting apoptotic pathways in melanoma -- Anti-angiogenesis therapy in melanoma -- Melanoma antigens recognized by T lymphocytes -- Melanoma vaccines -- Adoptive cell therapy for the treatment of metastatic melanoma -- Anti-CTLA-4 monolonal antibodies -- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co-stimulatory agents -- Novel cytokines for immunotherapy of melanoma -- Modulating the tumor microenvironment | ||
520 | |a Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers | ||
650 | 4 | |a Oncology | |
650 | 4 | |a Cancer research | |
700 | 1 | |a Gajewski, Thomas F. |e Sonstige |4 oth | |
700 | 1 | |a Hodi, F. Stephen |e Sonstige |4 oth | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781617794063 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781627038768 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781617794087 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-1-61779-407-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-SME |a ZDB-2-SXM | ||
940 | 1 | |q ZDB-2-SME_2012 | |
999 | |a oai:aleph.bib-bvb.de:BVB01-033029865 | ||
966 | e | |u https://doi.org/10.1007/978-1-61779-407-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_2012 |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1804183106406580224 |
---|---|
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
building | Verbundindex |
bvnumber | BV047645727 |
collection | ZDB-2-SME ZDB-2-SXM |
ctrlnum | (ZDB-2-SME)978-1-61779-407-0 (OCoLC)1289776456 (DE-599)BVBBV047645727 |
dewey-full | 616.994 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 616 - Diseases |
dewey-raw | 616.994 |
dewey-search | 616.994 |
dewey-sort | 3616.994 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
discipline_str_mv | Medizin |
doi_str_mv | 10.1007/978-1-61779-407-0 |
edition | 1st ed. 2012 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03521nmm a2200457zc 4500</leader><controlfield tag="001">BV047645727</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">211216s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781617794070</subfield><subfield code="9">978-1-61779-407-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-61779-407-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-61779-407-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1289776456</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047645727</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted Therapeutics in Melanoma</subfield><subfield code="c">edited by Thomas F. Gajewski, F. Stephen Hodi</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2012</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIV, 378 Seiten)</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Current Clinical Oncology</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Molecular targets and subtypes in melanoma -- Melanoma genomics -- Predictive biomarkers as a guide to future therapy selection in melanoma -- KIT as a therapeutic target for melanoma -- Targeted inhibition of B-Raf -- The notch and B-catenin pathways -- STAT3 and Src signaling in melanoma -- Targeting the mTOR, PI3K and AKT pathways in melanoma -- Targeting apoptotic pathways in melanoma -- Anti-angiogenesis therapy in melanoma -- Melanoma antigens recognized by T lymphocytes -- Melanoma vaccines -- Adoptive cell therapy for the treatment of metastatic melanoma -- Anti-CTLA-4 monolonal antibodies -- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co-stimulatory agents -- Novel cytokines for immunotherapy of melanoma -- Modulating the tumor microenvironment</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer research</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gajewski, Thomas F.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodi, F. Stephen</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781617794063</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781627038768</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781617794087</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-61779-407-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield><subfield code="a">ZDB-2-SXM</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2012</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033029865</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-61779-407-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_2012</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV047645727 |
illustrated | Not Illustrated |
index_date | 2024-07-03T18:48:42Z |
indexdate | 2024-07-10T09:18:10Z |
institution | BVB |
isbn | 9781617794070 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033029865 |
oclc_num | 1289776456 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | 1 Online-Ressource (XIV, 378 Seiten) Illustrationen |
psigel | ZDB-2-SME ZDB-2-SXM ZDB-2-SME_2012 ZDB-2-SME ZDB-2-SME_2012 |
publishDate | 2012 |
publishDateSearch | 2012 |
publishDateSort | 2012 |
publisher | Humana Press |
record_format | marc |
series2 | Current Clinical Oncology |
spelling | Targeted Therapeutics in Melanoma edited by Thomas F. Gajewski, F. Stephen Hodi 1st ed. 2012 Totowa, NJ Humana Press 2012 1 Online-Ressource (XIV, 378 Seiten) Illustrationen txt rdacontent c rdamedia cr rdacarrier Current Clinical Oncology Molecular targets and subtypes in melanoma -- Melanoma genomics -- Predictive biomarkers as a guide to future therapy selection in melanoma -- KIT as a therapeutic target for melanoma -- Targeted inhibition of B-Raf -- The notch and B-catenin pathways -- STAT3 and Src signaling in melanoma -- Targeting the mTOR, PI3K and AKT pathways in melanoma -- Targeting apoptotic pathways in melanoma -- Anti-angiogenesis therapy in melanoma -- Melanoma antigens recognized by T lymphocytes -- Melanoma vaccines -- Adoptive cell therapy for the treatment of metastatic melanoma -- Anti-CTLA-4 monolonal antibodies -- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co-stimulatory agents -- Novel cytokines for immunotherapy of melanoma -- Modulating the tumor microenvironment Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers Oncology Cancer research Gajewski, Thomas F. Sonstige oth Hodi, F. Stephen Sonstige oth Erscheint auch als Druck-Ausgabe 9781617794063 Erscheint auch als Druck-Ausgabe 9781627038768 Erscheint auch als Druck-Ausgabe 9781617794087 https://doi.org/10.1007/978-1-61779-407-0 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Targeted Therapeutics in Melanoma Oncology Cancer research |
title | Targeted Therapeutics in Melanoma |
title_auth | Targeted Therapeutics in Melanoma |
title_exact_search | Targeted Therapeutics in Melanoma |
title_exact_search_txtP | Targeted Therapeutics in Melanoma |
title_full | Targeted Therapeutics in Melanoma edited by Thomas F. Gajewski, F. Stephen Hodi |
title_fullStr | Targeted Therapeutics in Melanoma edited by Thomas F. Gajewski, F. Stephen Hodi |
title_full_unstemmed | Targeted Therapeutics in Melanoma edited by Thomas F. Gajewski, F. Stephen Hodi |
title_short | Targeted Therapeutics in Melanoma |
title_sort | targeted therapeutics in melanoma |
topic | Oncology Cancer research |
topic_facet | Oncology Cancer research |
url | https://doi.org/10.1007/978-1-61779-407-0 |
work_keys_str_mv | AT gajewskithomasf targetedtherapeuticsinmelanoma AT hodifstephen targetedtherapeuticsinmelanoma |